GlucoTrack shares rise 10.90% after-hours as new patents for blood glucose monitoring are announced.

GlucoTrack, Inc. (GCTK) surged 10.90% in after-hours trading following the announcement of three new patents for its proprietary Continuous Blood Glucose Monitoring (CBGM) platform, approved by the U.S. Patent and Trademark Office. The patent approvals, reported by Exec Edge six days prior, highlight the company’s technological advancements in diabetes management, potentially strengthening its competitive position and long-term growth prospects. This development aligns with the stock’s upward movement, as intellectual property milestones often signal innovation and market differentiation in healthcare sectors. Earlier news, including a private placement and quarterly results, appears less impactful given their older timestamps and lack of direct correlation to the recent price surge.